Poster Session 3-14 MDS: Clinical (5)

[PS3-14-2] Efficacy of azacitidine for MDS in clinical practice; at multiple facilities in Nagasaki prefecture

Eo Toriyama¹, Tomoko Hata^1,2, Masahiko Chiwata³, Rena Kamijo⁴, Masataka Taguchi², Masatoshi Matsuo⁵, Daisuke Ogawa⁶, Emi Matsuo⁷, Kensuke Horio⁸, Yumi Takasaki⁹, Takeshi Fujimoto¹⁰, Yasuhisa Kawaguchi¹⁰, Jun Taguchi⁸, Tatsuro Jo⁸, Hideki Tsushima⁵, Shinichiro Yoshida³, Yukiyoshi Moriuchi⁴, Hidehiro Itonaga², Shinya Sato², Koji Ando², Yasushi Sawayama², Yoshitaka Imaizumi², Yasushi Miyazaki^1,2 (1.Hematology, Atomic Bomb Disease institute, Nagasaki University, Nagasaki, Japan, 2.Hematology, Nagasaki University Hospital, Nagasaki, Japan, 3.Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan, 4.Hematology, Sasebo City General Medical Center, Sasebo, Japan, 5.Hematology, Nagasaki Harbor Medical Center, Nagasaki, Japan, 6.Internal Medicine, Nagasaki Prefecture Shimabara Hospital, Shimabara, Japan, 7.Hematology, JCHO Isahaya General Hospital, Isahaya, Japan, 8.Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 9.Internal Medicine, Saint Francis Hospital, Nagasaki, Japan, 10.Internal Medicine, National Hospital Organization Nagasaki Hospital, Nagasaki, Japan)